Literature DB >> 17920884

New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation.

Mike Frohn1, Han Xu, Xiaoming Zou, Catherine Chang, Michele McElvaine, Matthew H Plant, Min Wong, Philip Tagari, Randall Hungate, Roland W Bürli.   

Abstract

We report the development of the novel N-substituted benzimidazole 11 as a potent and selective human formyl peptide receptor-like 1 (hFPRL1) agonist. This compound and its less active enantiomer 12 were identified as useful tools for studying receptor function in vitro.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17920884     DOI： 10.1016/j.bmcl.2007.09.043

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  16 in total

1.  Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2010-09-15       Impact factor: 6.514

2.  Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.

Authors:  Clemencia Pinilla; Bruce S Edwards; Jon R Appel; Tina Yates-Gibbins; Marc A Giulianotti; Jose L Medina-Franco; Susan M Young; Radleigh G Santos; Larry A Sklar; Richard A Houghten
Journal:  Mol Pharmacol       Date:  2013-06-20       Impact factor: 4.436

Review 3.  Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.

Authors:  Mauro Perretti; Jesmond Dalli
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

Review 4.  Novel anti-inflammatory--pro-resolving mediators and their receptors.

Authors:  Charles N Serhan; Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 5.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

6.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Authors:  Agostino Cilibrizzi; Igor A Schepetkin; Gianluca Bartolucci; Letizia Crocetti; Vittorio Dal Piaz; Maria Paola Giovannoni; Alessia Graziano; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Bioorg Med Chem       Date:  2012-04-27       Impact factor: 3.641

7.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

8.  3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2012-12-03       Impact factor: 5.858

9.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

10.  Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function.

Authors:  A Planagumà; T Domenech; I Jover; I Ramos; S Sentellas; R Malhotra; M Miralpeix
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.